B.Braun LogoB.Braun Logo
    • Solutions

      • B2B & Industry Partners
      • Medication Management in Oncology
      • Smart Infusion Management
      • Surgical Asset & Supply Management
    • Therapies

      • Continence Care and Urology
      • Extracorporeal Blood Treatment Therapies
      • Infection Prevention and Control
      • Infusion Therapy
      • Interventional Vascular Therapy
      • Minimally Invasive Surgery
      • Neurosurgery
      • Nutrition Therapy
      • Oncology
      • Orthopaedic Surgery
      • Pain Therapy
      • Pediatrics & Neonatology
      • Spine Surgery
      • Surgical Instruments & Sterile Container Systems
      • Surgical Power Systems
      • Sutures & Surgical Specialities
      • Wound Management
    Find the product you are looking for. Visit the B. Braun product catalog with our complete portfolio. 

    Product Catalog

    Find the product you are looking for. Visit the B. Braun product catalog with our complete portfolio. 

    • Conditions

      • Chronic Kidney Disease
      • Hip, Knee  & Spine Surgery
      • Urinary Retention
    We offer a comprehensive range of services, tailored to every stage of the condition. For more information, please visit our Chronic Kidney Disease page.

    Chronic Kidney Disease

    We offer a comprehensive range of services, tailored to every stage of the condition. For more information, please visit our Chronic Kidney Disease page.

    • Our Culture

      • Working at B. Braun
    • Your Opportunities

      • Your Benefits
      • Work and career
    Discover your career opportunities at B. Braun. Search our global job market for interesting job profiles. 

    Find Your Job

    Discover your career opportunities at B. Braun. Search our global job market for interesting job profiles. 

    • Company

      • Facts & Figures
      • Vision & Values
      • Brand
      • Innovation Hub
    • Responsibility

      • Sustainability
      • Diversity
      • Compliance
      • Access to Health Care
      • Sponsoring & Donations
    • Media

      • Press Releases
      • Publication
    • Contact

      • Locations
      • Contact Form
    Let us drive innovation in medical technology together. Learn more about our innovation hub and present your idea.

    Innovation Hub

    Let us drive innovation in medical technology together. Learn more about our innovation hub and present your idea.

    In dialog with B. Braun. Get in touch with us.

    Contact

    In dialog with B. Braun. Get in touch with us.

  • Products & Solutions
    • Solutions
      • B2B & Industry Partners
      • Medication Management in Oncology
      • Smart Infusion Management
      • Surgical Asset & Supply Management
    • Therapies
      • Continence Care and Urology
      • Extracorporeal Blood Treatment Therapies
      • Infection Prevention and Control
      • Infusion Therapy
      • Interventional Vascular Therapy
      • Minimally Invasive Surgery
      • Neurosurgery
      • Nutrition Therapy
      • Oncology
      • Orthopaedic Surgery
      • Pain Therapy
      • Pediatrics & Neonatology
      • Spine Surgery
      • Surgical Instruments & Sterile Container Systems
      • Surgical Power Systems
      • Sutures & Surgical Specialities
      • Wound Management
  • Patient Care
    • Conditions
      • Chronic Kidney Disease
      • Hip, Knee  & Spine Surgery
      • Urinary Retention
  • Career
    • Our Culture
      • Working at B. Braun
    • Your Opportunities
      • Your Benefits
      • Work and career
  • About us
    • Company
      • Facts & Figures
      • Vision & Values
      • Brand
      • Innovation Hub
    • Responsibility
      • Sustainability
      • Diversity
      • Compliance
      • Access to Health Care
      • Sponsoring & Donations
    • Media
      • Press Releases
      • Publication
    • Contact
      • Locations
      • Contact Form
Language country combination selection page
Malaysia
  • Imprint
  • Terms and conditions
  • Terms of Use
  • Privacy Policy

Not all products are registered and approved for sale in all countries or regions. Indications of use may also vary by country and region. Please contact your country representative for product availability and information. Product images are for reference only.

Copyright © B. Braun Medical Industries Sdn. Bhd. - version 1.50.1
  • Home
  • Interventional Vascular Therapy
  • Angioplasty
  • DCB – Peripheral Drug Coated Balloons
  • SeQuent® Please OTW

<p>SeQuent® Please OTW</p>-<p>Peripheral drug coated balloon catheter</p>
<p>SeQuent® Please OTW</p>-<p>Peripheral drug coated balloon catheter</p>
<p>SeQuent® Please OTW</p>-<p>Peripheral drug coated balloon catheter</p>

SeQuent® Please OTW
Peripheral drug coated balloon catheter

SeQuent® Please OTW features an optimized and clinically proven drug-coating technology which facilitates the safe and effective treatment of patients with peripheral arterial disease (PAD) in above and below the knee indications. [1, 2]

As pioneers and global market leaders in drug-coated balloon catheter technologies that help interventionalists achieve the treatment strategy of leaving (almost) nothing behind, B. Braun brings extensive knowledge to the peripheral field with the SeQuent® Please OTW.

An effective next generation combination of Paclitaxel and Resveratrol [1,2]

SeQuent® Please OTW features an optimized and clinically proven drug-coating technology which facilitates the safe and effective treatment of patients with peripheral arterial disease.

Long-term efficacy with short-term drug release [1,2]

  • Paclitaxel with an effective drug dose of 3μg/mm² [3,4]
  • Significant reduction of TLR and in late lumen loss (LLL) compared to uncoated balloons [1,2,5]

Resveratrol: A naturally occurring matrix builder

  • Naturally occurring, plant-based substance found for example in the skin of red grapes & raspberries [5]
  • Acts as matrix builder and makes the Paclitaxel bioavailable [5]
  • Enables fast and effective drug transfer into vessel wall [5]

Mechanically resistant coating (5)

  • Homogeneous coating even in the balloon folds exceeding distal and proximal markers [5]
  • Low drug loss in simulated use [5]
  • Efficient available drug dose at inflation [1,2,5]

CONSEQUENT Demonstrates Safety and Efficacy

Safety and efficacy of SeQuent® Please OTW was demonstrated in an unselected, all comers cohort [2] whereas two-year efficacy and safety was shown in the CONSEQUENT RCT [1,4].

Read more

SeQuent® Please OTW features an optimized and clinically proven drug-coating technology which facilitates the safe and effective treatment of patients with peripheral arterial disease (PAD) in above and below the knee indications. [1, 2]

As pioneers and global market leaders in drug-coated balloon catheter technologies that help interventionalists achieve the treatment strategy of leaving (almost) nothing behind, B. Braun brings extensive knowledge to the peripheral field with the SeQuent® Please OTW.

An effective next generation combination of Paclitaxel and Resveratrol [1,2]

SeQuent® Please OTW features an optimized and clinically proven drug-coating technology which facilitates the safe and effective treatment of patients with peripheral arterial disease.

Long-term efficacy with short-term drug release [1,2]

  • Paclitaxel with an effective drug dose of 3μg/mm² [3,4]
  • Significant reduction of TLR and in late lumen loss (LLL) compared to uncoated balloons [1,2,5]

Resveratrol: A naturally occurring matrix builder

  • Naturally occurring, plant-based substance found for example in the skin of red grapes & raspberries [5]
  • Acts as matrix builder and makes the Paclitaxel bioavailable [5]
  • Enables fast and effective drug transfer into vessel wall [5]

Mechanically resistant coating (5)

  • Homogeneous coating even in the balloon folds exceeding distal and proximal markers [5]
  • Low drug loss in simulated use [5]
  • Efficient available drug dose at inflation [1,2,5]

CONSEQUENT Demonstrates Safety and Efficacy

Safety and efficacy of SeQuent® Please OTW was demonstrated in an unselected, all comers cohort [2] whereas two-year efficacy and safety was shown in the CONSEQUENT RCT [1,4].

References

[1] Albrecht T et al. Cardiovasc Intervent Radiol. 2018 Jul;41(7):1008-14.
[2] Langhoff R et al. Angiology. 2021 Mar 29:3319721997314.
[3] Tepe G et al. N Engl J Med. 2008 Feb 14;358(7):689-99.
[4] Tepe G et al. Cardiovasc Intervent Radiol. 2017 Oct;40(10):1535-44.
[5] Data on file at B. Braun.